Mark G. Kris, MD
The emergence of osimertinib (Tagrisso) in the EGFR
-positive non–small cell lung cancer (NSCLC) treatment paradigm has led to unprecedented progression-free survival (PFS) in patients, said Mark G. Kris, MD. Now, researchers are channeling their efforts into optimizing patient selection for and outcomes with the targeted therapy.
... to read the full story